Skip to Content
MilliporeSigma
All Photos(1)

Documents

I9885

Sigma-Aldrich

Anti-Human IgG (γ-chain specific), F(ab′)2 fragment antibody produced in goat

affinity isolated antibody, lyophilized powder

Synonym(s):

Goat Anti-Human IgG

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

MDL number:
MFCD00162442
UNSPSC Code:
12352203
NACRES:
NA.46

biological source

goat

Quality Level

200

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

secondary antibodies

clone

polyclonal

form

lyophilized powder

packaging

pkg of 5x1 mg
pkg of 1 mg

storage condition

avoid repeated freeze/thaw cycles

technique(s)

Ouchterlony double diffusion: suitable
quantitative precipitin assay: suitable

color

white to off-white

solubility

water: soluble, clear to hazy, colorless (after reconstitution with 1 ml of 0.135 M NaCl)

storage temp.

2-8°C

target post-translational modification

unmodified

General description

IgG antibody subtype is the most abundant serum immunoglobulins of the immune system. It is secreted by B cells and is found in blood and extracellular fluids and provides protection from infections caused by bacteria, fungi and viruses. Maternal IgG is transferred to fetus through the placenta that is vital for immune defence of the neonate against infections. Anti-Human IgG (γ-chain specific), F(ab′)2 fragment antibody is specific for human IgG subclasses. The F(ab′)2 fragment of the antibody is obtained from pepsin-digested antiserum by immunospecific methods of purification.

Immunogen

Purified human IgG

Application

Anti-Human IgG (γ-chain specific), F(ab′)2 fragment antibody is suitable for Ouchterlony double diffusion and quantitative precipitin assay. The antibody was used in ELISA and to produce Fab′-oligonucleotide conjugates.

Physical form

Lyophilized from 0.01 M sodium phosphate, 0.015 M sodium chloride, pH 7.2

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

H Brandstätter et al.
Vox sanguinis, 103(3), 201-212 (2012-04-14)
Complement factor H (CFH) acts as major regulator of the alternative pathway of complement and its mutations and polymorphisms predispose to various human diseases. We aimed to develop a scalable purification process of CFH from human plasma fractions to supply
Francesco Lolli et al.
Journal of neuroimmunology, 167(1-2), 131-137 (2005-07-30)
Synthetic glycopeptides have the potential to detect antibodies in multiple sclerosis (MS). In the present study, we analyzed the antibodies (IgM class, IgG class and IgG subclasses) to the synthetic glycopeptide CSF114(Glc) in the serum of 186 MS patients, 166
Hiroyasu Muramatsu et al.
Scientific reports, 11(1), 2160-2160 (2021-01-27)
Myostatin, a member of the transforming growth factor-β superfamily, is an attractive target for muscle disease therapy because of its role as a negative regulator of muscle growth and strength. Here, we describe a novel antibody therapeutic approach that maximizes
Z N Chaudri et al.
FEBS letters, 450(1-2), 23-26 (1999-06-01)
The covalent conjugation of oligonucleotides to antibody Fab' fragments was optimized by using oligonucleotides modified with a hexaethylene linker arm bearing three amino groups. One oligonucleotide was coupled to antibody of one specificity and a complementary oligonucleotide to antibody of
Christian Loch et al.
Journal of pharmaceutical sciences, 103(2), 517-526 (2013-12-07)
Intravitreal injections and drug-loaded implants are current approaches to treat diseases of the posterior eye. To investigate the release of active agents and their distribution in the vitreous body, a new test system was developed that enables a realistic simulation
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service